Navigation Links
Ventas Completes Previously Announced Sale of Common Stock
Date:2/1/2008

Company Receives Net Proceeds of $191.9 Million

LOUISVILLE, Ky., Feb. 1 /PRNewswire-FirstCall/ -- Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company") announced today that it has completed the sale of 4,485,000 shares of its common stock pursuant to the Company's existing shelf registration statement. The amount includes 585,000 shares of common stock that were sold pursuant to the exercise of the underwriter's overallotment option. The Company received net proceeds, before expenses, of $191.9 million, which the Company will use to repay indebtedness outstanding under its revolving credit facility and for working capital and other general corporate purposes, including to fund future acquisitions. As previously announced, the shares were sold to UBS Investment Bank, as sole underwriter, at a price of $42.78 per share.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Ventas, Inc. is a leading healthcare real estate investment trust. Its diverse portfolio of properties located in 43 states and two Canadian provinces includes seniors housing communities, skilled nursing facilities, hospitals and medical office and other properties.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Ventas, Inc.'s ("Ventas" or the "Company") and its subsidiaries' expected future financial position, results of operations, cash flows, funds from operations, dividends and dividend plans, financing plans, business strategy, budgets, projected costs, capital expenditures, competitive positions, acquisitions, investment opportunities, merger integration, growth opportunities, expected lease income, continued qualification as a real estate investment trust ("REIT"), plans and objectives of management for future operations and statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will" and other similar expressions are forward-looking statements. Such forward-looking statements are inherently uncertain, and security holders must recognize that actual results may differ from the Company's expectations. The Company does not undertake a duty to update such forward-looking statements, which speak only as of the date on which they are made.

The Company's actual future results and trends may differ materially depending on a variety of factors discussed in the Company's filings with the Securities and Exchange Commission. Factors that may affect the Company's plans or results include without limitation: (a) the ability and willingness of the Company's operators, tenants, borrowers, managers and other third parties, as applicable, to meet and/or perform the obligations under their various contractual arrangements with the Company; (b) the ability and willingness of Kindred Healthcare, Inc. (together with its subsidiaries, "Kindred"), Brookdale Living Communities, Inc. (together with its subsidiaries, "Brookdale") and Alterra Healthcare Corporation (together with its subsidiaries, "Alterra") to meet and/or perform their obligations to indemnify, defend and hold the Company harmless from and against various claims, litigation and liabilities under the Company's respective contractual arrangements with Kindred, Brookdale and Alterra; (c) the ability of the Company's operators, tenants, borrowers and managers, as applicable, to maintain the financial strength and liquidity necessary to satisfy their respective obligations and liabilities to third parties, including without limitation obligations under their existing credit facilities; (d) the Company's success in implementing its business strategy and the Company's ability to identify, underwrite, finance, consummate and integrate diversifying acquisitions or investments, including those in different asset types and outside the United States; (e) the nature and extent of future competition; (f) the extent of future or pending healthcare reform and regulation, including cost containment measures and changes in reimbursement policies, procedures and rates; (g) increases in the Company's cost of borrowing; (h) the ability of the Company's operators and managers, as applicable, to deliver high quality services, to attract and retain qualified personnel and to attract residents and patients; (i) the results of litigation affecting the Company; (j) changes in general economic conditions and/or economic conditions in the markets in which the Company may, from time to time, compete; (k) the Company's ability to pay down, refinance, restructure and/or extend its indebtedness as it becomes due; (l) the movement of interest rates and the resulting impact on the value of and the accounting for the Company's interest rate swap agreement; (m) the Company's ability and willingness to maintain its qualification as a REIT due to economic, market, legal, tax or other considerations; (n) final determination of the Company's taxable net income for the year ended December 31, 2007; (o) the ability and willingness of the Company's tenants to renew their leases with the Company upon expiration of the leases and the Company's ability to relet its properties on the same or better terms in the event such leases expire and are not renewed by the existing tenants; (p) risks associated with the acquisition of Sunrise Senior Living REIT ("Sunrise REIT"), including the timely delivery of accurate property-level financial results for the Company's properties and the Company's ability to timely and fully realize the expected revenues and cost savings therefrom; (q) factors causing volatility in the Company's revenues generated by the properties acquired in connection with the acquisition of Sunrise REIT, including without limitation national and regional economic conditions, costs of materials, energy, labor and services, employee benefit costs and professional and general liability claims; (r) the movement of U.S. and Canadian exchange rates; (s) year-over-year changes in the Consumer Price Index and the effect of those changes on the rent escalators, including the rent escalator for Master Lease 2 with Kindred, and the Company's earnings; (t) the impact on the liquidity, financial condition and results of operations of the Company's operators, tenants, borrowers and managers, as applicable, resulting from increased operating costs and uninsured liabilities for professional liability claims, and the ability of the Company's operators, tenants, borrowers and managers to accurately estimate the magnitude of such liabilities; and (u) the impact of the Sunrise Senior Living, Inc. strategic review process and accounting, legal and regulatory issues. Many of these factors are beyond the control of the Company and its management.

Contacts: Debra A. Cafaro

Chairman, President and CEO

or

Richard A. Schweinhart

Executive Vice President and CFO

(502) 357-9000


'/>"/>
SOURCE Ventas, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
2. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
3. Ventas Announces 2007 Third Quarter Earnings Release Date and Conference Call
4. Ventas Appoints Brush SVP - Senior Housing Development and Operations
5. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
6. Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance
7. Ventas Enters Agreement to Sell Common Stock
8. Eligard(R) six-month formulation successfully completes European approval procedure
9. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
10. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
11. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... The Texas Cord ... recently to the labor and delivery team at Women’s Hospital at Renaissance in Edinburg ... give birth at the hospital and decide to donate. , “Women’s Hospital at ...
(Date:4/28/2017)... , ... April 28, 2017 , ... People are starting ... people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa wore ... Associates of Greater Boston, in a NALA North American Speaker Series (NASS) ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... York (PRWEB) , ... April 28, 2017 , ... ... anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, ... the hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... Rochester, NY (PRWEB) , ... April 28, 2017 ... ... is celebrating its 5th anniversary. SearchLight is the premier online modeling resource for ... “With more than 30,000 active users during last 5 years spanning the globe, ...
Breaking Medicine News(10 mins):
(Date:4/26/2017)... PROVIDENCE, N.J. , April 26, 2017 Phoenix ... announce its fifteenth year of fulfilling its mission of transforming ... industry is highly scrutinized, Phoenix,s innovative ... the healthcare community about the latest advances in science and ... Phoenix was founded in 2002 by ...
(Date:4/21/2017)... 21, 2017 Halo Labs announces the launch ... analysis system called the Horizon at PEGS 2017 in ... new system analyzes sub visible particulate matter in biopharmaceutical ... screening as early as candidate selection and pre-formulation. ... contract research organization Elion Labs for system ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
Breaking Medicine Technology: